The US health regulator has changed its strain recommendation for the 2024-25 COVID-19 vaccines, as it asked manufacturers to update the new shots to...
Moderna said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and...
Scientists at University of California Riverside have demonstrated a new, RNA-based vaccine strategy that is effective against any strain of a virus and can...
Nigeria has become the first country in the world to roll out the "revolutionary" new Men5CV vaccine against meningitis, the World Health Organization (WHO)...
The emergency global stockpile of cholera vaccines is empty with all available doses for this month already allocated to countries battling major outbreaks,...
Low vaccination rates against the latest versions of COVID-19 and influenza are putting pressure on healthcare systems this winter, leading public health officials told...
Novavax's updated vaccine has been granted emergency-use authorization by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12...
GSK said Arexvy, its vaccine for respiratory syncytial virus (RSV) showed positive preliminary results in a late-stage trial to protect adults aged 50 to...
Moderna on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly-mutated BA.2.86 subvariant of the coronavirus...
Moderna said on Thursday an initial study data showed its updated COVID-19 vaccine to be effective against the "Eris" and "Fornax" subvariants in humans.
The...
Merck and Moderna on Wednesday announced the initiation of the late-stage trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with...
Pfizer's experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing severe infections in infants when given to expecting mothers in the second...
Sinopharm said on Friday its biotech unit has received regulatory approval for clinical trials of its mRNA COVID-19 vaccine targeting the Omicron variant.
The unit,...
Vaccines company Valneva on Monday reported positive 12-month antibody persistence data for its single-shot Chikungunya vaccine candidate.
The firm said in a statement it was...